Please login to the form below

Not currently logged in
Email:
Password:

NDA Group appoints new vice president

Dr Werner Van den Eynde will also lead its advisory board

Regulatory affairs consultancy group NDA has appointed Dr Werner Van den Eynde as its new vice president to head up its advisory board providing strategic advice to pharmaceutical clients during its drug development life cycle.

Eynde comes to the Swiss group with international pharmaceutical experience, having held senior positions for the likes of GE Healthcare, Abbott and Solvay Pharmaceuticals.

His new role will see him manage strategy operations and development of the NDA advisory board, including business development, sales, marketing and service development.

He said: “NDA is the perfect platform for anyone who wants to have a positive impact on drug development across the world and the excellent reputation of the NDA advisory board is wide spread.

“Building on an almost twenty year tradition of unbiased advice to drug developing companies, I’m very motivated to continue the NDA success story and expand the advisory board to meet the future demands that science, technology and the regulatory environment put on companies developing therapies for patients.”

Eynde joins the group from Chemo – Exeltis where he was head of R&D, regulatory affairs and pharmacovigilance.

Johan Stromquist, chief executive officer, NDA Group, said: “ With his [Eynde] experience in drug development, following the process from many perspectives, he will be able to add tremendous value to clients in all stages of development, as well as create tailored teams and services of great benefit to the drug development industry.”

6th September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics